We're excited to share that our portfolio company, Axial Biotherapeutics, has been selected as one of FierceBiotech's Fierce 15...
Read more
We are delighted to announce that Chimera Bioengineering is the latest company to join the Kairos portfolio. Founded in...
Read more
We are pleased to announce that Transient Plasma Systems (TPS) is the latest company to join the Kairos portfolio....
Read more
Healthline recently published an article on the importance of implantable drugs, including Delpor’s implant devices. The first half of...
Read more
This month, Axial Biotherapeutics announced the appointment of leading experts in the Autism Spectrum Disorders (ASD) field to its...
Read more
We are proud to announce that Kairos Venture Partners II, L.P., our second fund, has made its second investment...
Read more
We are excited to announce that Kairos Venture Partners II, L.P., our second fund, has made its first investment...
Read more
Kairos portfolio company, Compellon, appointed software and services veteran Carv Moore as its Chief Executive Officer to lead the...
Read more
The NIDDK continues to fund Delpor's efforts to utilize its NANOPOR™ technology in developing a matchstick-size subcutaneous implant device...
Read more
Delpor will be part of the Innovation Zone, a high profile 6,000 square foot exhibit space dedicated to showcasing...
Read more